semaglutide and arrhythmia New-Onset Atrial Fibrillation Potentially Associated With Tirzepatide: A Case Report Semaglutide and AFib: Heart Safety

Tirzepatide weight loss injections are given once weekly

According to the SURMOUNT-5 trial published in May 2025, participants on the maximum tolerated dose of Semaglutide (1.7 mg or 2.4 mg) achieved an average weight loss of 13.7% over 72 weeks

Originally developed for type 2 diabetes, it has also been FDA-approved for chronic weight management, demonstrating significant, sustained weight loss in clinical trials

For the majority of GLP-1 users, digestive symptoms are part of what researchers describe as a gut adaptation phase

Hitting a Nerve This can happen during intramuscular or intravenous (into the vein) injections

A.DrachmannT.et al